In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Xenon Genetics advances triglyceride drug discovery program
Xenon and Novartis Sign Drug Development Deal for Obesity and Metabolic Disorders
Xenon Genetics Awarded $4.7 million in Funding from Genome Canada and Genome BC
Myriad discovers novel proteins in heart disease
Arexis acquires project in lipid metabolism from AstraZeneca
Xenon Enters Cardiovascular Disease Collaboration with Merck & Co., Inc.
ALTANA selects Cyprotex for drug discovery support
Medicure acquires novel cholesterol-lowering technology platform
De Novo and Geneformatics announce drug discovery collaboration